BACKGROUND AND PURPOSE: The purpose of this study was to determine the distribution of polyethylene glycol-conjugated superoxide dismutase in the brain, cerebrospinal fluid, and various organs. METHODS: Distribution of iodine-125-labeled polyethylene glycol-conjugated superoxide dismutase was determined in three groups of male Sprague-Dawley rats: a normotensive sham control group (n = 9) and groups given 125I-labeled polyethylene glycol-conjugated superoxide dismutase either 30 minutes before (n = 10) or 30 minutes after (n = 7) norepinephrine-induced hypertensive injury. RESULTS: In the first 30 minutes after intravenous administration, polyethylene glycol-conjugated superoxide dismutase plasma activity declined to 70% of the initial value and then decreased negligibly between 30 and 90 minutes. Levels of 125I-labeled polyethylene glycol-conjugated superoxide dismutase in normotensive animals were low in the brain and cerebrospinal fluid and highest in kidney. Brain levels of polyethylene glycol-conjugated superoxide dismutase were elevated only in those rats that received it before hypertensive injury; however, cerebrospinal fluid levels were elevated in animals receiving the drug either before or after hypertensive injury. CONCLUSION: Our results suggest that the blood-brain barrier becomes more permeable to polyethylene glycol-conjugated superoxide dismutase only during the hypertensive period but that the blood-cerebrospinal fluid barrier sustains more permanent injury. We suggest that the therapeutic effectiveness of polyethylene glycol-conjugated superoxide dismutase in hypertensive brain injury is due to its action in the vascular wall or to its extracellular activity in the cerebrospinal fluid.
BACKGROUND AND PURPOSE: The purpose of this study was to determine the distribution of polyethylene glycol-conjugated superoxide dismutase in the brain, cerebrospinal fluid, and various organs. METHODS: Distribution of iodine-125-labeled polyethylene glycol-conjugated superoxide dismutase was determined in three groups of male Sprague-Dawley rats: a normotensive sham control group (n = 9) and groups given 125I-labeled polyethylene glycol-conjugated superoxide dismutase either 30 minutes before (n = 10) or 30 minutes after (n = 7) norepinephrine-induced hypertensive injury. RESULTS: In the first 30 minutes after intravenous administration, polyethylene glycol-conjugated superoxide dismutase plasma activity declined to 70% of the initial value and then decreased negligibly between 30 and 90 minutes. Levels of 125I-labeled polyethylene glycol-conjugated superoxide dismutase in normotensive animals were low in the brain and cerebrospinal fluid and highest in kidney. Brain levels of polyethylene glycol-conjugated superoxide dismutase were elevated only in those rats that received it before hypertensive injury; however, cerebrospinal fluid levels were elevated in animals receiving the drug either before or after hypertensive injury. CONCLUSION: Our results suggest that the blood-brain barrier becomes more permeable to polyethylene glycol-conjugated superoxide dismutase only during the hypertensive period but that the blood-cerebrospinal fluid barrier sustains more permanent injury. We suggest that the therapeutic effectiveness of polyethylene glycol-conjugated superoxide dismutase in hypertensive brain injury is due to its action in the vascular wall or to its extracellular activity in the cerebrospinal fluid.
Authors: Erin G Rosenbaugh; James W Roat; Lie Gao; Rui-Fang Yang; Devika S Manickam; Jing-Xiang Yin; Harold D Schultz; Tatiana K Bronich; Elena V Batrakova; Alexander V Kabanov; Irving H Zucker; Matthew C Zimmerman Journal: Biomaterials Date: 2010-04-07 Impact factor: 12.479
Authors: Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova Journal: J Control Release Date: 2015-03-31 Impact factor: 9.776
Authors: Jing Tong; Xiang Yi; Robert Luxenhofer; William A Banks; Rainer Jordan; Matthew C Zimmerman; Alexander V Kabanov Journal: Mol Pharm Date: 2012-12-17 Impact factor: 4.939
Authors: Xiang Yi; Matthew C Zimmerman; Ruifang Yang; Jing Tong; Serguei Vinogradov; Alexander V Kabanov Journal: Free Radic Biol Med Date: 2010-05-20 Impact factor: 7.376
Authors: Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman Journal: Am J Physiol Regul Integr Comp Physiol Date: 2013-04-03 Impact factor: 3.619
Authors: Natalia L Klyachko; Devika S Manickam; Anna M Brynskikh; Svetlana V Uglanova; Shu Li; Sheila M Higginbotham; Tatiana K Bronich; Elena V Batrakova; Alexander V Kabanov Journal: Nanomedicine Date: 2011-07-29 Impact factor: 5.307